Down regulation of MHC-II expression in serial passages of allogenic bone marrow derived stromal cells for cell based therapy

Order of Publishing in Issue: 
Volume :2
Issue :2
March, 2008
Page No: 
Lakshmi Kiran Chelluri*, Vasantha Adavi, G P V S. Subbaiah, K S. Ratnakar and K. Ravindranath
Transplant Biology & Stem Cells, Global Hospitals, Hyderabad-500004, India
Correspondence:Lakshmi Kiran Chelluri,Ph.D Head, Transplant Biology & Stem Cell Global Hospitals, Lakdi-ka- Pool, Hyderabad - 500 004, India

Mesenchymal stem cells (MSC) show evidence of being potential candidates for allogenic application; however test methods toevaluate their suitability are not yet well established. The study evaluates the possible role of histocompatible markers for routine preclinicalscreening of MSCs for cell based therapies. The results in 5 healthy, prospective, allogenic donor-recipient pairs in co-cultureexperiments demonstrated downregulation of MHC-II expression up until passage 5. The lack of HLA-DR in cytotoxicity assays are suggestive of hypoimmunogenic nature of MSC’s. The preproof-of concept in the current study throws new light in the potential wider clinical applicability  of mesenchymal stem cells.

Mesenchymal stem cells (MSC), Hypoimmunogenicity, Stro-1, MLR, MSC crossmatching.
85-95.pdf632.12 KB

To download full text articles and issues in PDF at no cost.All you have to do is fill out a brief registration form. It's easy and it's free. At any time, you may request removal of your contact information from our database.
Click here to Register | Click here if you have already registered

2018 ABAP Awards

Invitation for Nominations to 2019 ABAP Awards
The Association of Biotechnology and Pharmacy invites nominations for the following awards from the eligible talented people with proven track record and achievements on or before August 31, 2019 in the prescribed format.



Upcoming 0 events

  • No upcoming events available

User login